Gables Capital Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.09M Sell
16,302
-50
-0.3% -$5.85K 0.76% 33
2026
Q1
$1.97M Sell
16,352
-550
-3% -$63.5K 0.83% 34
2025
Q4
$1.78M Sell
16,902
-400
-2% -$37.5K 0.75% 37
2025
Q3
$1.45M Buy
17,302
+275
+2% +$22.6K 0.62% 42
2025
Q2
$1.35M Sell
17,027
-1,850
-10% -$147K 0.64% 39
2025
Q1
$1.69M Buy
18,877
+875
+5% +$81.7K 0.84% 32
2024
Q4
$1.79M Buy
18,002
+450
+3% +$46.4K 0.86% 31
2024
Q3
$1.99M Buy
17,552
+1,715
+11% +$204K 1.01% 27
2024
Q2
$1.96M Sell
15,837
-150
-0.9% -$19.3K 1.03% 26
2024
Q1
$2.11M Sell
15,987
-100
-0.6% -$12.3K 1.16% 22
2023
Q4
$1.75M Sell
16,087
-95
-0.6% -$9.86K 1.09% 24
2023
Q3
$1.67M Sell
16,182
-16
-0.1% -$1.73K 1.16% 24
2023
Q2
$1.87M Buy
16,198
+135
+0.8% +$15.3K 1.22% 22
2023
Q1
$1.71M Buy
16,063
+43
+0.3% +$4.64K 1.19% 23
2022
Q4
$1.78M Sell
16,020
-35
-0.2% -$3.58K 1.29% 21
2022
Q3
$1.38M Hold
16,055
1.11% 25
2022
Q2
$1.46M Buy
16,055
+150
+0.9% +$13.3K 1.11% 26
2022
Q1
$1.3M Hold
15,905
0.82% 36
2021
Q4
$1.22M Hold
15,905
0.73% 35
2021
Q3
$1.2M Sell
15,905
-80
-0.5% -$6.08K 0.78% 38
2021
Q2
$1.24M Sell
15,985
-12,144
-43% -$903K 0.85% 35
2021
Q1
$2.07M Sell
28,129
-1,258
-4% -$92.8K 1.13% 26
2020
Q4
$2.29M Sell
29,387
-524
-2% -$40.1K 1.34% 23
2020
Q3
$2.37M Sell
29,911
-125
-0.4% -$9.79K 1.53% 21
2020
Q2
$2.22M Buy
30,036
+640
+2% +$48.2K 1.54% 21
2020
Q1
$2.16M Buy
29,396
+854
+3% +$67.1K 1.77% 17
2019
Q4
$2.48M Sell
28,542
-1,431
-5% -$118K 1.66% 18
2019
Q3
$2.41M Buy
29,973
+2,987
+11% +$239K 1.7% 15
2019
Q2
$2.16M Buy
26,986
+1,289
+5% +$98.7K 1.76% 16
2019
Q1
$2.04M Buy
25,697
+404
+2% +$30.2K 1.64% 19
2018
Q4
$1.84M Sell
25,293
-786
-3% -$55.5K 1.61% 19
2018
Q3
$1.76M Buy
26,079
+68
+0.3% +$4.33K 1.34% 23
2018
Q2
$1.49M Buy
26,011
+686
+3% +$38.7K 1.22% 26
2018
Q1
$1.32M Buy
+25,325
New +$1.37M 1.16% 27

Other funds holding MRK

Gables Capital Management's MRK Position: Q2 2026 in Review

Gables Capital Management reduced its Merck (MRK) stake by 0.31% in Q2 2026, selling an estimated $5.85K and leaving 16,302 shares worth $2.09M. The position accounts for 0.76% of the portfolio, ranked #33.

Gables Capital Management first reported a position in MRK in Q1 2018 and has held it in 34 quarters since. The position peaked at $2.48M in Q4 2019. 3,820 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Gables Capital Management held 16,302 shares of Merck worth $2.09M as of Q2 2026.
  • Gables Capital Management sold 50 Merck shares in Q2 2026, an estimated $5.85K.
  • Merck made up 0.76% of Gables Capital Management's portfolio in Q2 2026, its #33 holding.
  • Gables Capital Management first reported a position in Merck in Q1 2018 and has held it in 34 quarters since.
  • Gables Capital Management's Merck position peaked at $2.48M in Q4 2019.
  • 3,820 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.